The LOS was greater among patients with a [TIMP-2] × [IGFBP7] level greater than 2.0 (ng/mL)2/1000 compared with 2.0 (ng/mL)2/1000 or less (11 days [IQR, 7-20 days] vs 8 days [IQR, 5-13 days]; P < .001), and among patients with standard KDIGO criteria for AKI (pooling stages 1-3), the presence of a [TIMP-2] × [IGFBP7] level greater than 2.0 (ng/mL)2/1000 was associated with a longer hospital LOS than among patients with a [TIMP-2] × [IGFBP7] level of 2.0 (ng/mL)2/1000 or less (11 days [IQR, 7-20 days] vs 9 days [IQR, 6-14 days]; P = .008). This evidence concerns the gene TIMP2 and acute kidney injury.